Our Company

NeoBiotechnologies is a leader in advancing immuno-oncology research and transforming cancer treatment.

Our extensive product range includes over 10,000 monoclonal antibody products, targeting various types of cancer including solid tumors and hematological malignancies. The product portfolio is diverse and technologically advanced, with a focus on HuProtTM Validated Antibodies. This high-throughput technology ensures antibody specificity, binding affinity, and potential cross-reactivity against various target proteins, making them highly reliable for experiments. NeoBiotechnologies’ primary antibodies are key in cancer research and diagnostics, enabling researchers to investigate protein functions, interactions, and expression patterns.

Our collection of monoclonal antibodies, produced using hybridoma and recombinant techniques, are renowned for their precision and consistency. They are used widely for their ability to recognize and bind to a single, predetermined target, such as disease-causing proteins, viruses, or cancer cells. We offer monoclonals from different hosts like mice, rabbits, and rats, and ensure lot-to-lot consistency through sequencing and recombinant production techniques.

NeoBiotechnologies’ recombinant monoclonal antibodies, developed through genetic manipulation techniques, are a key highlight. These antibodies are produced by cloning specific antibody-producing cells from immunized animals and incorporating their variable complementarity-determining regions (CDRs) into a recombinant expression system. Recombinant Monoclonal antibodies offer precision targeting, consistency, and reproducibility, and are widely used in Immunohistochemistry (IHC), Western Blotting (WB), Immunofluorescence (IF) applications, immunoprecipitation assays, and other research and diagnostic applications.

NeoBiotechnologies also specializes in Transcription Factor Antibodies, offering a portfolio of about 1300 antibodies developed under an NIH Grant. These antibodies are crucial for probing gene expression mechanisms, with implications for a wide range of scientific and medical applications.

Furthermore, we are committed to collaboration and actively engage in partnerships with researchers and institutions worldwide to optimize our antibodies, pushing the boundaries of cancer research and treatment. Our commitment to innovation and quality places us at the forefront of immuno-oncology research.

NeoBiotechnologies’ antibodies undergo rigorous validation processes including SDS-PAGE Analysis Validation, Flow Cytometry Validation, Immunofluorescence Validation, Western Blot Antibody Validation, and Purity and Sequencing. They are tested on the HuProtTM Protein Array, containing over 21,000 full-length proteins, to assess antibody specificity, epitope mapping, binding affinity, and reproducibility. NeoBiotechnologies is the original manufacturer of several key cancer biomarkers, including the Transthyrethin Prealbumin Antibody, ACTH (Adrenocorticotrophic Hormone) (N-Terminal) (Pituitary Marker) Antibody, Alkaline Phosphatase (Placental) / PLAP (Germ Cell Tumor Marker) Antibody, Smooth Muscle Actin (Leiomyosarcoma Marker) Antibody, Beta-2 Microglobulin (Renal Failure & Tumor Marker) Antibody, CD45 / LCA (B-Cell Marker) Antibody, PCNA (Proliferating Cell Nuclear Antigen) (G1- & S-phase Marker) Antibody, and the CA19-9/Sialyl Lewisa (GI Tumor Marker) Antibody.

NeoBiotechnologies stands out for its comprehensive range of high-quality, validated antibodies, cutting-edge technology, and commitment to advancing cancer research and diagnostics.